DM
KERX

Deerfield Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Deerfield Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-700,000
Closed -$9.63M – 145
2014
Q3 		$9.63M Buy
+700,000
New +$10.7M 0.35% 71

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Deerfield Management's KERX Position: Q1 2017 in Review

Deerfield Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2017, closing a stake of 1,291,531 shares — an estimated $7.57M sold.

Deerfield Management first reported a position in KERX in Q2 2013 and held it in 9 quarters. The position peaked at $59.7M in Q2 2014. 119 funds tracked by Wall St. Rank hold KERX as of Q1 2017.

  • Deerfield Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Deerfield Management sold 1,291,531 Keryx Biopharmaceuticals Inc shares in Q1 2017, an estimated $7.57M.
  • Deerfield Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 9 quarters.
  • Deerfield Management's Keryx Biopharmaceuticals Inc position peaked at $59.7M in Q2 2014.
  • 119 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2017.

Based on Deerfield Management's 13F filing for Q1 2017, filed 15 May 2017.